Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 2/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.43 |
| ▸ | CCNK | O75909 | 3/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3344755 | 0.80 | GNRHR (0.43) | GNRHR | |
| SCHEMBL10191562 | 0.75 | NPC1 (0.43) | GNRHR | |
| SCHEMBL3327972 | 0.74 | GNRHR (0.42) | GNRHR | |
| SCHEMBL12058648 | 0.73 | KMT2A (0.47) | — | |
| SCHEMBL3334090 | 0.73 | RORC (0.43) | GNRHR | |
| SCHEMBL10190995 | 0.72 | GNRHR (0.43) | GNRHR | |
| SCHEMBL10191014 | 0.71 | GNRHR (0.38) | GNRHR | |
| SCHEMBL18838986 | 0.70 | USP30 (0.54) | IRAK4EGLN2 | |
| SCHEMBL3325879 | 0.70 | DPP4 (0.52) | IRAK4CCNKCDK12CCNA2CDK2 | |
| SCHEMBL3326230 | 0.70 | DPP4 (0.52) | IRAK4CCNKCDK12CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653125-B2 | Cyclohexane derivative having NPY Y5 receptor antagonism | SHIONOGI CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | NPY5R, NPY1R, NPY2R | GNRHR 55/4885IRAK4 2733/4885CCNK 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.